Boehringer Ingelheim

Boehringer IngelheimThe Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

www.boehringer-ingelheim.com

Boehringer Ingelheim RSS Channel

Display # 
Title Published Date
The European Stroke Organisation and Boehringer Ingelheim launch the "Angels Initiative" 21 July 2016
Boehringer Ingelheim and Lilly announce clinical trial collaboration in metastatic breast cancer 13 July 2016
Boehringer Ingelheim and Harvard scientists establish a research alliance 07 June 2016
Boehringer Ingelheim increases access to the medication for the treatment of HIV/AIDS 30 May 2016
Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing 23 May 2016
New analysis shows only minority of COPD patients may benefit from inhaled corticosteroids 12 April 2016
Boehringer Ingelheim launches RE-COVERY DVT/PE™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate) 24 March 2016
European Commission confirms CMDh recommendation: Benefit/risk profiles of ambroxol and bromhexine products are favorable 25 January 2016
Boehringer Ingelheim and Arena Pharmaceuticals collaborate to advance research in schizophrenia 19 January 2016
Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer 22 December 2015
Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate) 26 November 2015
Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years 12 November 2015
Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research 11 November 2015
Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic regulators of COPD 22 September 2015
International survey shows quality of patient-physician conversation at diagnosis linked to better patient outcomes 17 September 2015
Boehringer Ingelheim and Circuit Therapeutics announce new collaboration to discover novel medicines for obesity 14 August 2015
Patients reporting better quality of communication by their physician show improved self-care 08 June 2015
Eureka Therapeutics Inc. and Boehringer Ingelheim announce a collaboration to identify next generation antibodies for cancer treatment 26 May 2015
Boehringer Ingelheim acquires Pharmaxis' phase 1 anti-inflammatory drug candidate 19 May 2015
Boehringer Ingelheim positioned for future growth with product launches 28 April 2015

Most Popular Now

New antibiotic Zavicefta approved i…

AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a ne...

Read more

Novo Nordisk and Aarhus University …

Novo Nordisk and Aarhus University's Science and Technology faculty today signed a collaboration agreement to strengthen protein technology research and development. Unde...

Read more

AstraZeneca enters licensing agreem…

AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, ...

Read more

Novartis adds bispecific antibodies…

Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. Th...

Read more

Bristol-Myers Squibb and PsiOxus Th…

Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an exclusive clinical collaboration agreement to evaluate the safety, to...

Read more

Bristol-Myers Squibb acquires Cormo…

Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormo...

Read more

Sanofi Pasteur signs research agree…

Sanofi and its vaccines global business unit Sanofi Pasteur announced today a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Resear...

Read more

FDA advances Precision Medicine Ini…

In support of the President’s Precision Medicine Initiative, the U.S. Food and Drug Administration has issued two draft guidances that, when finalized, will provide a fle...

Read more

Merck and Pfizer initiate Phase III…

Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) have announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of ave...

Read more

Merck commits €1.5 million to the G…

Merck, a leading science and technology company, today announced it would continue to support the advancement of medical science in the field of fertility through the Gra...

Read more

Laboratory drug trials could lead t…

A new drug with the potential to reverse or slow the development of asthma is being tested by researchers at The University of Queensland. Developed by international phar...

Read more

Twisting and turning to target anti…

Researchers are getting closer to understanding how some natural antibiotics work so they can develop drugs that mimic them. A recent review commissioned by the British g...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

© World Pharma News 2006 - 2016